Oncimmune Regulatory News (ONC)

3 September 2020

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Publication of cost-effectiveness study assessing EarlyCDT Lung in lung cancer amongst patients with Indeterminate Pulmonary Nodules

EarlyCDT Lung and CT surveillance was found to be highly cost-effective compared to CT surveillance alone with an incremental cost-effectiveness ratio (ICER) of less than £2,500

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, is pleased to note the publication by PLOS ONE of a study led by Leeds University Academic Unit of Health Economics, supported by NIHR Leeds In Vitro Diagnostics Co-operative ("NIHR Leeds MIC"), and funded by The National Institute for Health Research's ("NIHR") SBRI Healthcare programme, which evaluated the cost-effectiveness of the EarlyCDT Lung blood test in combination with Computed Tomography ("CT"), compared to CT surveillance alone in the diagnosis of lung cancer amongst patients with Indeterminate Pulmonary Nodules ("IPNs").

The results of the study demonstrate that at an example cost of £70 per test, the EarlyCDT Lung blood test will have a positive impact on the outcomes of those patients observed, and when used alongside CT surveillance, is a cost-effective approach to the management of patients with IPNs. The study calculates the ICER to be £2,417, substantially below the accepted £20,000 per QALY ("quality adjusted life year") threshold set by NICE.

According to Cancer Research UK1., there are approximately 50,000 new cases of lung cancer every year, making lung cancer the third most common cancer in the UK. Furthermore, lung cancer is the most common cause of cancer deaths in the UK, with 5- and 10-year survival rates as low as 10% and 5%, respectively. This highlights the need to detect and correctly treat lung cancer as early as possible.

The online publication at PLOS ONE can be accessed here: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0237492 

1. https://www.cancerresearchuk.org/about-cancer/lung-cancer

Adam M Hill, CEO of Oncimmune said: "We are very pleased with the results of this study, demonstrating the cost effectiveness of the EarlyCDT Lung blood test as an adjunct to the diagnostic management of IPNs. The Leeds University Academic Unit of Health Economics and NIHR Leeds MIC were excellent delivery partners for this project. This study has enabled the generation of further data for the EarlyCDT Lung blood test that supports its adoption in ongoing discussions with healthcare providers across the UK."

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000

WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000

About Oncimmune

Our intimate understanding of the human immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies.

The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and give people extra time. Oncimmune's immunodiagnostic test, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis.

The unique combination of our core technology and understanding of the immune system, powers our ImmunoINSIGHTS service; a proprietary platform that enables life science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.

Oncimmune was founded in 2002 and launched its platform diagnostic technology in 2009, followed by the launch of its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 200,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) Early detection of Cancer of the Lung ("ECLS") trial of 12,208 high-risk smokers in Scotland. This trial demonstrated that EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is EarlyCDT Lung?

EarlyCDT is a simple blood test that detects the elevated presence of autoantibodies generated by the body's immune system as a natural defence against cancer cells.

EarlyCDT Lung is the world's most thoroughly validated blood test for the detection of lung cancer and requires only a small volume of blood which can be taken using a test in the home or community setting as well as a doctor's surgery. Shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis, EarlyCDT Lung can also provide an effective assessment of cancer risk in indeterminate pulmonary nodules (IPNs).

For more information, visit www.oncimmune.com